F&O expiry: Sensex ends choppy trade on flat note, gains 6% in Aug series

Sectorally, the metals pack bled the most, down 1.3 per cent, followed by the PSB Index (down 0.8 per cent)

9:19 AM

Nifty snapshot

9:18 AM

Sensex heat map

Bajaj Finserv among top gainers

9:16 AM

Markets open for trade

9:06 AM

COMMODITY CHECK :: Gold, silver futures trade with negative bias

9:05 AM

Sensex Heatmap :: Top gainers & losers in pre-open session

9:04 AM

Nifty slips marginally in pre-open trade

9:03 AM

Pre-open session :: Sensex climbs 175 points

8:56 AM

Indian indices perform better than emerging market counterparts in 2021

The Indian markets have outperformed their emerging market (EM) peers on a year-to-date (YTD) basis, supported by a combination of favourable short-term and medium-term factors. The benchmark Nifty has gained 17 per cent YTD in dollar terms, the best returns amongst headline EM indices. READ MORE

8:48 AM

Top stocks to watch today

Bharti Airtel: The telecom operator said on Wednesday its board will meet on August 29 to consider various capital raising via equity or equity linked or debt instruments.

 

Bank of India: State-owned Bank of India on Wednesday approved the launch of QIP at a floor price of Rs 66.19 per equity share, and aimed at raising Rs 3,000 crore equity capital. READ MORE

8:44 AM

Bulk deals on the NSE as on Wednesday

Click here for complate list

8:41 AM

Bulk deals on the BSE as on Wednesday

Click here for complete list

8:39 AM

Jefferies raises its FY22-24 EPS estimates for Voltas by 2-5%

>> Had announced Voltbek JV in 2016-17 with Rs 500 crore investment

>> The JV is at a turning point

>> Our estimates factor Voltbek JV reasing Break-Even point by FY25

8:37 AM

JPMorgan on Marico

Reco: Overweight | TP: Rs 600

>> It offers double digit revenue growth and portfolio diversification

>> Valuation attractive relative to peers

>> Ebitda margin is likely to stay in healthy zone of 19-20%

>> Seeing strong recovery for VAHO & healthy momentum for Saffola Edible Oil

8:34 AM

Morgan Stanley maintains 'Overweight' on Gujarat Gas

>> GG has raised prices by 4-12% across portfolio

>> See limited impact of the move as its customers are hiking prices too

>> TP: Rs 733

8:30 AM

IIFL on Cipla

Cipla has defined 10 Strategic Business Objectives in its FY21 AR, with the company maintaining focus on superior execution across its branded home markets of India & SA and portfolio expansion in the US respiratory & complex generics space. While Albuterol market-share ramp-up has allowed Cipla to maintain steady US sales as against the sharp erosion witnessed by peers, the recent Brovana launch along with upcoming launches (Qvar, Abraxane & Advair) will drive further traction in the US business over the next 2-3 years.

Factoring of trade receivables has driven significant reduction in WCap intensity, thereby enabling Cipla to generate USD680m cumulative FCF during FY20 & FY21. We expect the strong US product launch momentum to drive cumulative FCF of USD1.3bn over FY22-24ii and RoIC to improve to 20/26% in FY23/24ii. Cipla remains our top-pick among large-cap pharma.

Pharma stocks